Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Procrit epoetin alfa: Phase III data

Researchers published in Gynecologic Oncology updated data from the Phase III GOG-191 trial showing that cervical cancer patients receiving Procrit

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE